Skip to content
OpenCapital
Get started

LivaNova LIVN Italian MedTech payback measure

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept livn:MedicalDevicePaybackCurrent.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is LivaNova's italian medtech payback measure?
LivaNova (LIVN) reported italian medtech payback measure of $13.33M in Q1 2026.
How has LivaNova's italian medtech payback measure changed year-over-year?
LivaNova's italian medtech payback measure decreased by 24.2% year-over-year, from $17.59M to $13.33M.
What is the long-term trend for LivaNova's italian medtech payback measure?
Over 3 years (2022 to 2025), LivaNova's italian medtech payback measure has grown at a 26.0% compound annual growth rate (CAGR), from $6.41M to $12.84M.